Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021
Aptose Biosciences (Nasdaq: APTO; TSX: APS) will announce its financial results for Q1 2021 on May 4, 2021, after market close. The announcement will be followed by a conference call at 4:30 PM ET. Investors can access the call via dial-in or webcast. The Q1 report will include financial statements and management’s discussion available on SEDAR and EDGAR. Aptose focuses on developing therapies for unmet needs in oncology, particularly in hematology, with investigational products luxeptinib and APTO-253 undergoing clinical trials.
- Aptose is advancing its clinical-stage pipeline, focusing on effective cancer therapies.
- Luxeptinib and APTO-253 are both undergoing clinical trials targeting significant malignancies.
- None.
SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market.
| Conference Call & Webcast: | |
| Date: | Tuesday, May 4, 2021 |
| Time: | 4:30 PM ET |
| Dial In - Toll-Free: | 1 844-882-7834 |
| Dial In - International: | 1 574-990-9707 |
| Conference ID: | 2788133 |
| Webcast: | https://edge.media-server.com/mmc/p/bnrjs6pf |
| Replay available through May 11, 2020: | |
| Dial In - Toll-Free: | 1 855-859-2056 |
| Dial In - International: | 1 404-537-3406 |
| Conference ID: | 2788133 |
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at https://www.aptose.com/investors/news-events/ir-calendar. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the year and quarter ended March 31, 2021 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical- stage investigational products for hematologic malignancies: luxeptinib (formerly CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).
For further information, please contact:
| Aptose Biosciences Inc. | LifeSci Advisors, LLC |
| Susan Pietropaolo | Dan Ferry, Managing Director |
| Investor Relations | 617-535-7746 |
| 201-923-2049 | Daniel@LifeSciAdvisors.com |
| spietropaolo@aptose.com |
FAQ
When will Aptose report its Q1 2021 financial results?
What time is Aptose's conference call on May 4, 2021?
How can I access Aptose's financial statements for Q1 2021?
What are the investigational products being developed by Aptose?
